iBio
IBIO • AMEX
iBio is a biotechnology company in the healthcare sector trading on AMEX, led by CEO Martin Brenner, with a market cap of $70.0M.
CEOMartin Brenner
Market Cap$70.0M
Biotechnology
Healthcare
Employees23.0
Websiteibioinc.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for iBio
Date
Friday, May 1, 2026 (in 3 months)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q3 2026
EPS Estimate
-$0.05
Revenue Estimate
$60.0K
Earnings History
Past 11 earnings reports for iBio
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 12, 2025 | Q1 2026 | -$0.11Est: -$0.07 | -57.1% | $100.0KEst: $55.0K | +81.8% |  10-Q/A |
| Sep 5, 2025 | Q4 2025 | -$0.32Est: -$0.25 | -28.0% | $200.0KEst: $100.0K | +100.0% | 10-K |
| May 2, 2025 | Q3 2025 | -$0.49Est: -$0.32 | -53.1% | -Est: $100.0K | -100.0% | 10-Q |
| Feb 10, 2025 | Q2 2025 | -$0.48Est: -$0.32 | -50.0% | $200.0K | — | 10-Q |
| Nov 12, 2024 | Q1 2025 | -$0.46Est: -$0.48 | +4.2% | - | — | 10-Q |
| Sep 20, 2024 | Q4 2024 | -$0.91Est: -$0.48 | -89.6% | $175.0K | — | 10-K/A |
| May 13, 2024 | Q3 2024 | -$0.71 | — | - | — | 10-Q |
| Feb 9, 2024 | Q2 2024 | -$2.42 | — | - | — | 10-Q |
| Nov 14, 2023 | Q1 2024 | -$4.20Est: -$8.20 | +48.8% | $50.0K | — | — |
| Sep 27, 2023 | Q4 2023 | -$1.80 | — | - | — | — |
| May 15, 2023 | Q3 2023 | -$9.40Est: -$10.80 | +13.0% | -Est: $200.0K | -100.0% | — |